Page 83 - Amgen News Today

WESPAC Advisors LLC bought a new stake in Amgen Inc. (NASDAQ:AMGN – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 4,088 shares of the medical research company’s stock, valued at approximately $1,177,000. Other institutional investors have also added to […]

Aull & Monroe Investment Management Corp reduced its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 1.8% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 12,440 shares of the medical research company’s stock after selling 224 shares during the quarter. Amgen accounts for about 1.8% of Aull & Monroe Investment […]

WESPAC Advisors LLC bought a new position in Amgen Inc. (NASDAQ:AMGN – Free Report) in the fourth quarter, HoldingsChannel reports. The institutional investor bought 4,088 shares of the medical research company’s stock, valued at approximately $1,177,000. A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. […]

WESPAC Advisors LLC bought a new stake in Amgen Inc. (NASDAQ:AMGN – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 4,088 shares of the medical research company’s stock, valued at approximately $1,177,000. Other institutional investors have also added to […]

Wallington Asset Management LLC lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 1.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 39,944 shares of the medical research company’s stock after acquiring an additional 455 shares during the […]

Muthiah Vaduganathan, MD, MPH, discusses a presentation from ACC.24 assessing the effects of dapagliflozin across a range of left ventricular hypertrophy from DELIVER.

Wallington Asset Management LLC boosted its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 1.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,944 shares of the medical research company’s stock after purchasing an additional 455 shares during the quarter. […]

Our economy is on the up and up, and investing is a must. Let's review the most undervalued S&P 500 stocks to buy in April.

- Succeeds Founding CEO, Dr. Someit Sidhu, who will continue as a Board Director - Recognized as inspirational industry leader with exceptional R&D, commercial and global executive experience -...

Trifecta Capital Advisors LLC grew its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 5.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,875 shares of the medical research company’s stock after purchasing an additional 482 shares during the quarter. […]